The second step takes place during HCC progression. Because expression characteristics Torin 1 cell line and functional data obtained in prostate and gastric cancer suggest a tumor suppressive function of AKAP12,6, 8 its down-regulation in the majority of CL and DN may contribute to the increased risk of malignant transformation. Because little is known about interaction of AKAP12 with other factors, we correlated AKAP12 expression

at the protein level with the expression of other factors involved in hepatocarcinogenesis. Cyclin D1 overexpression is a common finding in hepatocarcinogenesis, which has been shown to occur very early in hepatocarcinogenesis in mouse models.4, 5 In NIH3T3 cells, it has been shown that SSeCKS expression induces G1 LDE225 arrest marked by a decrease in cyclin D1 expression.21 Interestingly, our study did not reveal a statistically significant inverse correlation of AKAP12 with cyclin D1, although our TMA analysis showed increasing cyclin D1 levels during hepatocarcinogenesis. As expected, AKAP12 showed an inverse correlation with the proliferation

marker Ki-67. As we previously demonstrated, AKAP12 down-regulation may partly be caused by chromosomal loss of the AKAP12 gene locus (see Supporting Table 1).10 However, this finding did not sufficiently explain down-regulation of AKAP12 in most HCCs. Because aberrant methylation status has been identified to be of mechanistic selleck screening library and prognostic significance in human HCC,22 we tested epigenetic alterations in the AKAP12 promoter region. Our study demonstrates hypermethylation of AKAP12α promoter in human HCC specimens and in various HCC cell lines.

Thus, gene silencing by promoter hypermethylation may be the cause for the significant decrease of AKAP12 protein levels in HCC cells. This concept of AKAP12 down-regulation is in line with studies in lung and gastric cancer which described the AKAP12 gene as a target for epigenetic silencing.8, 23 Although existing antibodies fail to distinguish between AKAP12 isoforms, data on AKAP12α and β transcripts suggest that hypermethylation of the AKAP12α promoter is predominantly responsible for epigenetic silencing of AKAP12. This is supported by the fact that the highly methylated HCC cell line AKN1 decreased AKAP12α promoter methylation after 5-aza-dC treatment resulting in increased expression of AKAP12α mRNA. The distinct hypermethylation of only the AKAP12α promoter seems to be specific for human HCC, because data obtained in other malignancies, e.g., gastric cancer, showed a hypermethylation of both, AKAP12α and β promoter region.8 A coordinate control between the AKAP12 promoters might be involved in hepatocarcinogenesis; however, our data in human HCC do not support this hypothesis.